Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ...
The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback